Latest

• Development of the Patient and Public Involvement Questionnaire for Canadian Formulary Committees

  Lee Verweel MSc, Rachel Goren, Ahmed M. Bayoumi MSc MD, Kelly K. O’Brien PhD, Elaine MacPhail BSc MHP, Tamara Rader, James H. Tiessen PhD, Zahava R.S. Rosenberg-Yunger PhD »

• Death Denied or Death Delayed? Outcomes among Nova Scotia patients deemed ineligible for MAiD

  Caitlin Lees MD MA MSc, Gordon Gubitz MD, Robert Horton MD »

• Harassment Reporting Mechanisms for Physicians and Medical Trainees in Alberta

  Kendra Martel, Penelope Smyth MD FRCPC, Manpreet Dhillon BComm MEB, Doreen M. Rabi MD MSc FRCPC, Debrah Wirtzfeld MD MSc MBA FRCPC, Shannon M. Ruzycki MD MPH FRCPC »

• Advance Requests for MAiD in Dementia: Survey of Canadian Public and MAiD Practitioners

  Adrian C. Byram, PhD | Ellen R. Wiebe, MD | Sabrina Tremblay-Huet, LLD | Peter B. Reiner, VMD, PhD »

• Patented Medicines Expenditure in Canada 1990-2019

  CHPI Annual Research Series »

• Modernizing Canadian Pharmacists’ Scope of Practice for Controlled Drugs and Substances

  Zahava R.S. Rosenberg-Yunger, MA, PhD | Lisa D. Bishop, BScPharm, PharmD | Shelita Dattani, BScPharm, PharmD »

• Essais cliniques au Canada: signes inquiétants persistent malgré la réponse superficielle du CEPMB

  Nigel S B Rawson, PhD »

• Clinical Trials in Canada: Worrying Signs Remain Despite PMPRB’s Superficial Response

  Nigel S B Rawson, PhD »

• National Strategy for Drugs for Rare Diseases should Prioritize Patients not Cost Containment

  Nigel S B Rawson, PhD and John Adams, BA »